PUBLISHER: Grand View Research | PRODUCT CODE: 1321346
PUBLISHER: Grand View Research | PRODUCT CODE: 1321346
The global spatial genomics & transcriptomics market size is expected to reach USD 574.3 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 12.2% from 2023 to 2030. The market is poised for significant growth over the forecast period owing to the increasing potential of spatial genomic analysis as a cancer detection method and the advent of the latest generation of sequencing technology.
The shift toward personalized medicine, which aims to provide tailored healthcare based on individual characteristics, is driving the demand for spatial genomics and transcriptomics. These technologies offer a comprehensive view of the genetic and molecular landscape within patient tissues, enabling precise diagnosis, prognosis, and treatment selection. Spatial genomics and transcriptomics facilitate the identification of specific gene expression patterns associated with disease subtypes, allowing clinicians to make informed decisions about personalized treatment strategies.
The market for spatial genomics & transcriptomics has witnessed significant technological advancements in recent years. Companies have been investing in research and development to improve the accuracy, scalability, and affordability of spatial genomics and transcriptomics platforms. Additionally, the market has seen the introduction of user-friendly and integrated solutions that simplify data analysis and interpretation, making these technologies more accessible to a broader user base.
For instance, in April 2023, Vizgen launched the world's first single-cell spatial genomics platform based on MERFISH technology. The device offers high resolution and maximum efficiency to profile the transcriptome. These advancements have expanded the market potential and attracted investments from both academic and industry sectors.